-
Mashup Score: 32Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia - 7 day(s) ago
Reinfusion extended CAR T-cell persistence in 52% of patients reinfused for relapse prevention, thereby potentially reducing relapse risk.Reinfusion induce
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Tumor mutational load is prognostic for progression to therapy among high-count monoclonal B-cell lymphocytosis - 7 day(s) ago
Tumor mutational load is a strong prognostic factor for progression to therapy among individuals with HCMBL, independent of CLL-IPI.Accounting for both CLL
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia - 29 day(s) ago
Continuous venetoclax monotherapy for untreated or R/R del(17p) CLL led to a median PFS of 28.2 months and median OS of 62.5 months.Subgroup analysis sugge
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 34Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update - 1 month(s) ago
Tisagenlecleucel responses in patients with r/r FL remain highly durable a year after primary analysis; no new safety signals were observed.Low levels of L
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 52Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenström macroglobulinemia - 1 month(s) ago
Patients with Waldenström macroglobulinemia and mutations in CXCR4 or TP53 had poorer prognosis after treatment with BTKis.Patients with CXCR4 or TP53 muta
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 47A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen - 1 month(s) ago
DA-EPOCH-R and adjunctive ixazomib as frontline therapy in aggressive MYC-aberrant NHL is most effective in patients with DEL.Reasons for early discontinua
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 10A robust and validated integrated prognostic index for defining risk groups in adult acute lymphoblastic leukemia: an EWALL collaborative study - 2 month(s) ago
Integrating key risk factors (genetics, white blood cell count, and minimal residual disease) predicts outcome more accurately than using traditional risk facto
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 35The phase 2 LYSA study of prednisone, vinblastine, doxorubicin, and bendamustine for untreated Hodgkin lymphoma in older patients - 2 month(s) ago
The PVAB regimen yielded a CMR rate of 77.5% as a firstline therapy for older patients with HL, with acceptable toxicity.The 4-year cumulative risk of events wa
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 6Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL - 3 month(s) ago
iFCR followed by 2 years of ibrutinib maintenance led to sustained deep remission in CLL irrespective of immunoglobulin heavy-chain variable region gene status.
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 39Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia - 3 month(s) ago
The combination of ibrutinib and venetoclax induced deep and durable responses in treatment-naïve patients with Waldenström macroglobulinemia.Planned study ther
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
Reinfusion extended CAR T-cell persistence in 52% of patients reinfused for relapse prevention, thereby potentially reducing relapse risk. https://t.co/LYeH9g4w9j #clinicaltrialsandobservations #lymphoidneoplasia https://t.co/m1zOeyIlyW